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Key messages
What is already known on this subject?
To date, none of the available mechanical circulatory 
support devices significantly improves 30-day mortality 
in patients with cardiogenic shock due to acute 
myocardial infarction.
What does this study add?
Impella improves parameters of shock severity but is 
associated with higher bleeding complications and has 
no significant effect on 30-day mortality compared 
with the use of IABP.
How might this impact on clinical practice?
The benefit of Impella on mortality should be evaluated 
in an adequately powered randomised controlled trial.
AbstrAct
Objective We investigated the benefit of Impella, a 
modern percutaneous mechanical support (pMCS) device, 
versus former standard intra-aortic balloon pump (IABP) 
in acute myocardial infarction complicated by cardiogenic 
shock (AMICS).
Methods This single-centre, retrospective study included 
patients with AMICS receiving pMCS with either Impella 
or IABP. Disease severity at baseline was assessed with 
the IABP-SHOCK II score. The primary outcome was all-
cause mortality at 30 days. Secondary outcomes were 
parameters of shock severity at the early postimplantation 
phase. Adjusted Cox proportional hazards models identified 
independent predictors of the primary outcome.
Results Of 116 included patients, 62 (53%) received 
Impella and 54 (47%) IABP. Despite similar baseline 
mortality risk (IABP-SHOCK II high-risk score of 18 % vs 
20 %; p = 0.76), Impella significantly reduced the inotropic 
score (p < 0.001), lactate levels (p < 0.001) and SAPS II 
(p = 0.02) and improved left ventricular ejection fraction 
(p = 0.01). All-cause mortality at 30 days was similar 
with Impella and IABP (52 % and 67 %, respectively; p = 
0.13), but bleeding complications were more frequent in 
the Impella group (3 vs 4 units of transfused erythrocytes 
concentrates due to bleeding complications, p = 0.03). 
Previous cardiopulmonary resuscitation (HR 3.22, 95% CI 
1.76 to 5.89; p < 0.01) and an estimated intermediate (HR 
2.77, 95% CI 1.42 to 5.40; p < 0.01) and high (HR 4.32 
95% CI 2.03 to 9.24; p = 0.01) IABP-SHOCK II score were 
independent predictors of all-cause mortality.
Conclusions In patients with AMICS, haemodynamic 
support with the Impella device had no significant 
effect on 30-day mortality as compared with IABP. In 
these patients, large randomised trials are warranted to 
ascertain the effect of Impella on the outcome.
IntROduCtIOn
Acute myocardial infarction complicated 
by cardiogenic shock (AMICS) remains 
an important cause of death, despite early 
percutaneous coronary revascularisation.1 
Recent data show that in these patients, 
in-hospital mortality reaches 66% and long-
term mortality 80%.2
In patients with AMICS, the intra-aortic 
balloon pump (IABP) was used for mechan-
ical support for decades, but it was down-
graded from the guideline recommendations 
after the IABP-SHOCK II trial failed to show 
any mortality benefit over medical therapy 
alone.3 4 Impella (Abiomed, Danvers, Massa-
chusetts, USA) is a promising alternative for 
percutaneous mechanical circulatory support 
(pMCS) that has been utilised as a bridge to 
recovery. It consists of a miniaturised axial 
flow pump fitted onto a pigtail catheter, 
pumping blood from the left ventricle into 
the ascending aorta and providing a cardiac 
output of 2.5 L/min (Impella 2.5) and up 
to 4.0 L/min (Impella CP).5 6 It actively 
unloads the left ventricle reducing the stroke-
work and myocardial oxygen consumption, 
thereby providing cardioprotection and 
robust haemodynamic support.7–9
Two randomised controlled trials (RCT) 
and a metanalysis of RCTs investigated the 
benefit of Impella versus IABP, but they were 
highly underpowered to detect a mortality 
difference.10–12 Moreover, as noted from the 
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investigators of those trials, RCTs in the setting of AMICS 
are extremely difficult to conduct. Therefore, the profile 
of patients who may profit from support with Impella still 
remains unclear.
The aim of our study was to investigate the effect of 
Impella compared with IABP in patients with AMICS in 
terms of improvement of parameters of shock severity 
and all-cause mortality at 30 days.
MetHOds
study design and data collection
This retrospective study included patients with AMICS, 
who were treated with either Impella or IABP, from a 
historical cohort of two tertiary cardiovascular centres 
of the Charité-University Medicine in Berlin. Patients 
treated between January 2011 and March 2017 were 
included in the study. Data at baseline and at 30-day 
follow-up were collected from a computerised patient 
information system (COPRA Systems, Germany). The local 
ethics committee approved data collection. The results of 
the study are reported in accordance with the Strength-
ening the Reporting of Observational Studies in Epide-
miology guidelines.13
Inclusion and exclusion criteria
Inclusion
Patients with AMICS due to ST-segment elevation myocar-
dial infarction (STEMI) or non-STEMI (NSTEMI), with 
symptom onset within 24 hours of clinical presentation, 
were included. The shock was defined by the need for 
continuous administration of vasopressors for >30 min 
in order to maintain a systolic blood pressure of >90 
mm Hg, despite adequate fluid loading, evidence of 
end-organ hypoperfusion, clinical or radiological signs of 
pulmonary congestion and lactate serum concentration 
at clinical presentation >20 mg/dL.4
Exclusion
Exclusion criteria were: contraindication for device 
implantation, resuscitation lasting >30 min, presence of 
left ventricular thrombus, presence of a mechanical aortic 
valve, severe aortic valve stenosis, severe peripheral arterial 
disease precluding placement of Impella, significant right 
heart failure, presence of an atrial or ventricular septal 
defect including postinfarction ventricular septal defect, 
left ventricular rupture and cardiac tamponade. Online 
supplementary file 1 depicts the patient selection process.
Interventional and device therapy
The characteristics of IABP and Impella are described 
elsewhere.14 Operators were experienced in the use of 
both devices. Patients with AMICS underwent primary 
percutaneous coronary intervention (PCI) of the culprit 
lesion in accordance with current local guidelines.15 16 
In presence of multivessel disease, the modality of revas-
cularisation, that is, immediate versus staged PCI of the 
non-culprit lesion(s), was left to the discretion of the 
operator. Duration of mechanical support was guided 
by the treating intensive care physician. Weaning was 
achieved by a stepwise reduction of the amount of 
support provided by the pMCS device. In 2013, following 
the publication of the IABP-SHOCK II trial, the use of 
IABP was terminated and replaced by Impella.
Outcomes
The primary outcome was all-cause mortality at 30 days. 
Other outcomes were adverse cardiac events during 
hospitalisation, such as myocardial infarction (MI), target 
vessel revascularisation (TVR), stroke, and changes in 
parameters of shock severity (ie, improvement of cardiac 
power index (CPI), left ventricular ejection fraction 
(LVEF), serum lactate levels, and Simplified Acute Phys-
iology Score II (SAPS II)), reduction in the ICU stay and 
duration of device therapy. The recently published IABP-
SHOCK II score, a short-term mortality risk score, derived 
from patients included in the IABP-SHOCK II trial,17 was 
calculated in each patient, allowing the exploration of 
Impella effect on outcomes in each risk subcategory. The 
inotropic score and CPI were calculated over the first 5 
days, as previously described.18 LVEF was measured at 
admission, at the time of device weaning and at discharge 
by transthoracic echocardiography. Pre-PCI time interval 
was defined as the time interval from symptom onset 
to the first PCI balloon inflation. The pre-device time 
interval was defined as the time interval from symptom 
onset to device implantation. The bleeding complica-
tions were classified according to the Bleeding Academic 
Research Consortium (BARC) classification.19
statistical analysis
Data are expressed as medians with interquartile ranges 
(IQR) or frequencies and percentages, as appropriate. 
Normality of distribution was testes with the Shapiro-Wilk 
test. Wilcoxon rank sum for was used for comparisons of 
non-parametric variables and the Χ² test for categorical 
variables. Changes within the first 5 days for parameters of 
shock severity (CPI, inotropic score, lactate and SAPS II) 
and from baseline to discharge for LVEF were analysed 
using a generalised linear-mixed model considering the 
between and within-patient differences. Kaplan-Meier anal-
ysis estimated the cumulative incidence of mortality at 30 
days. Cox-regression analysis was performed to identify 
independent predictors of 30-day mortality while adjusting 
for potential confounding variables (IABP-SHOCK II 
risk score and cardiopulmonary resuscitation (CPR)). To 
assess the validity of the Cox proportional hazard model, 
the proportional assumption hazard was tested based on 
Schoenfeld residuals. All probability values were two-tailed 
and considered significant for p<0.05. Data analysis was 
performed using STATA V.14.0 statistical software.
Results
Baseline and procedural characteristics
Out of 116 included patients, 62 (53%) received Impella 
and 54 (47%) IABP. Table 1 outlines the baseline charac-
teristics of all patients and according to the device received. 
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Table 1 Baseline characteristics
Total
(N=116)
IABP
(N=54)
Impella
(N=62) P value
Age, years 72(64–77) 71(64–75) 73(62–79) 1.00
Male 85 (73) 41 (76) 44 (71) 0.67
BMI 26(24–29) 26(24–29) 26(25–29) 0.63
Smoke 29 (25) 19 (35) 10 (16) 0.02
Hypertension 70 (60) 34 (63) 36 (58) 0.70
Hyperlipidaemia 74 (64) 38 (70) 36 (58) 0.18
NIDDM 52 (45) 20 (37) 32 (51) 0.11
Previous stroke 7 (6.0) 3 (3.7) 5 (8.1) 0.44
Peripheral artery disease 5 (4.3) 3 (5.6) 2 (3.2) 0.66
Previous MI 18 (16) 7 (13) 11 (18) 0.61
Previous PCI 22 (19) 7 (13) 15 (24) 0.15
One-vessel CAD 18 (16) 7 (13) 11 (18) 0.35
Two-vessel CAD 27 (23) 12 (22) 15 (24) 0.35
Three-vessel CAD 68 (59) 35 (65) 33 (53) 0.35
CABG 3 (2.6) 0 (0) 3 (4.9) 0.24
Pre-existing cardiomyopathy 6 (5.2) 3 (5.5) 1 (1.6) 0.45
Pacemaker/CRT 5 (4.3) 1 (1.8) 4 (6.5) 0.37
CKD 20 (17) 8 (15) 12 (19) 0.62
CPR 70 (60) 32 (59) 38 (61) 0.45
 In hospital CPR 38 (54) 21 (66) 17 (45) 0.10
 Out of hospital CPR 32 (46) 11(34) 21 (55) 0.10
Index event AMI
 STEMI 82 (71) 40 (74) 42 (68) 0.54
 NSTEMI 34 (29) 14 (26) 20 (32) 0.45
Data depicted as median (IQR) or counts (%). P values are from Wilcoxon rank sum test or Fischer test.
AMI, acute myocardial infarction; BMI, body mass index; CABG, coronaryartery bypass graft; CAD, coronary artery disease; CKD, chronic 
kidney disease; CPR, cardiopulmonary resuscitation; CRP, C reactive protein; CRT, cardiac resynchronization therapy; IABP-SHOCK II, 
Intra-aortic Balloon Pump in Cardiogenic Shock II; LDH, lactate dehydrogenase; MI, myocardial infarction; NIDDM, non-insulin-dependent 
diabetes mellitus; PCI, percutaneous coronary intervention; Pre-PCI time, time from symptom onset to the first PCI balloon inflation; Pre-
device time, time from symptom onset to device implantation.
Table 2 IABP-SHOCK II risk score
Score
Total
(N=116)
IABP
(N=54)
Impella
(N=62) P value
Low (0–2) 40 (36) 17 (34) 23 (38) 0.68
Intermediate (3–4) 50 (45) 23 (46) 27 (44) 0.85
High (5–9) 21 (19) 10 (20) 11 (18) 0.79
Data depicted as counts (%). P values are from the Fischer test. 
Data on the IABP-SHOCK II risk score was notretrievable for five 
patients.
IABP-SHOCK II, Intra-aortic Balloon Pump in Cardiogenic Shock 
II.
The median age in the entire cohort was 72 years (IQR, 
64–77) and 73% were men. Demographic characteristics 
and cardiovascular risk factors were similarly distributed 
among groups, except for the history of smoking, signifi-
cantly more frequent in the IABP group. STEMI was the 
most frequent index event in both groups (Impella vs IABP: 
68% vs 74%; p=0.54). No significant differences regarding 
comorbidities, rate of out of or in-hospital CPR or the type 
of index event (ie, NSTEMI and STEMI) were observed. 
At the time of index event, 50% of patients presented in 
sinus rhythm, 22% in ventricular fibrillation and 11% in 
supraventricular arrhythmia (online supplementary file 1). 
Overall, no significant difference in the rate of different 
types of cardiac rhythm was observed. The baseline esti-
mated short-term mortality risk, calculated using the IABP-
SHOCK II score, was comparable among groups (table 2). 
The periprocedural characteristics are outlined in table 3. 
At baseline, patients treated with Impella had significantly 
worse LVEF (28 [20-35] vs 34 [30-39] %; p=0.01), and 
comparable SAPS II and serum lactate levels (60 [32-95] 
vs 49 [23-77] mg/dL; p=0.09). The size of MI was signifi-
cantly higher in patients receiving Impella (CK-max 2822 
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Table 3 Periprocedural characteristics
IABP
(N=54)
Impella
(N=62) P value
LVEF 34(30-39) 28(20-35) 0.01
SAPS II 60(48-74) 68(47-79) 0.16
Lactate, mg/dL 49(23-77) 60(32-95) 0.09
Creatinine, mg/dL 1.37 (1.08–1.89) 1.39 (1.14–1.75) 0.93
pH 7.22 (7.12–7.36) 7.25 (7.12–7.35) 0.59
Haemoglobin, g/dL 13.7 (11.8–14.6) 13.5 (12.1–14.3) 0.86
Glucose, mg/dL 302 (226–407) 340 (261–429) 0.18
CK-max., U/L 1330 ([473–4626) 2822 (887–6355) 0.04
CK-MB max., U/L 221 (68–544) 336 (109–680) 0.19
Pre-PCI time, min 121 (60–196) 111 (71–262) 0.42
Pre-device time, min 121 (82–228) 144(107–364) 0.17
Device implantation before stenting 29 (54) 34 (55) 1.00
TIMI flow at baseline
 TIMI 0 34 (63) 41 (66) 0.85
 TIMI I 12 (22) 17 (27) 0.17
 TIMI II 8 (15) 4 (6.5) 0.22
TIMI III flow after primary PCI* 31 (60) 47 (77) 0.07
Data depicted as median (IQR) or counts (%). P values are from Wilcoxon rank sum test or Fischer test.
*Data on TIMI III flow after PCI were not retrievable for two patients in the IABP and one patient in the Impella group.
CK-MB, Creatine kinase isoform MB; CK-max, maximal creatine kinase; CPR, cardiopulmonary resuscitation; LVEF, left ventricular ejection 
fraction; SAPS II, Simplified Acute Physiology Score II; TIMI, thrombolysis in myocardial infarction.
Table 4 Clinical and procedural characteristics at the ICU
IABP
(N=54)
Impella
(N=62) P value
Mechanical ventilation 51 (94) 60 (96) 0.66
Duration of mechanical ventilation, hours 36(12–168) 24(12–216) 0.73
Renal replacement therapy 21 (39) 24 (39) 1.00
Duration of dialysis, hours 48(24–84) 36(12–240) 0.95
Duration of device therapy, hours 24(12–36) 24(12–36) 0.74
Days of ICU stay 3(1–11) 3.5(1–18) 0.57
Successful weaning 30 (55) 36 (60) 0.70
Arrhythmias during device-therapy 17 (32) 17 (27) 0.68
  Supraventricular tachycardia 7 (13) 7 (11) 0.78
  Ventricular tachycardia 4 (7.4) 6 (9.7) 0.75
  Ventricular fibrillation 5 (9.2) 2 (3.2) 0.24
  Bradycardia 2 (3.7) 3 (4.8) 1.00
Data depicted as median [IQR] or counts (%). P values are from Wilcoxon rank sum or Fischer’s test.
IABP, intra-aortic balloon pump; ICU, intensive care unit.
[887–6355] vs 1330 [473–4626] U/L; p=0.04). There was 
no significant difference in the rate of device implanta-
tions before stenting (55% vs 54%; p=1.00), time to device 
implantation (144 vs 121 min; p=0.17) and postinterven-
tional TIMI III flow rates (77% vs 60%, p=0.07) in patients 
treated with Impella versus IABP.
Characteristics during hospitalisation
Clinical and procedural characteristics during the stay at 
the intensive care unit (ICU) are summarised in table 4. 
Overall, >90% of patients in both groups were mechanically 
ventilated for a median of 24 and 36 hours in the Impella 
and IABP group, respectively. In each group, 39% of patients 
received renal replacement therapy (RRT). The median 
duration of pMCS was 24 (12-36) hours in both groups, 
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Figure 1 Changes in clinical parameters and use of catecholamines during hospitalisation (A) inotropic score, B) serum lactate 
levels and (C) SAPS II from baseline to the fourth day after device implantation, and (D) LVEF from baseline to discharge are 
depicted. measurements are presented as median and 25th–75th percentile. P values are from a generalised linear model 
considering the between and within difference among groups. The catecholamine dose was evaluated by the inotropic score (µ/
kg/min.)=dopamine+dobutamine +100*epinephrine +100*norepinephrine +100*isoproterenol. IABP, intra-aortic balloon pump; 
LVEF, left ventricular ejection fraction; SAPS II, Simplified Acute Physiology Score II.
and more than half of were successfully weaned from each 
device (60% and 55%, Impella vs IABP, respectively). No 
significant difference regarding the duration of mechan-
ical ventilation, RRT, ICU stay and rate of device-triggered 
arrhythmias was observed. Although the use of catechola-
mines at admission and during the ICU stay was initially 
high for both devices, significantly faster weaning within 
the first 4 days was achieved in patients treated with Impella 
(figure 1A) However, the overall increase of CPI was not 
significantly different between the two groups (online 
supplementary file 1). Compared with patients treated 
with IABP, those treated with Impella displayed a signifi-
cant reduction of lactate levels and SAPS II within the first 
4 days after device implantation (figure 1B, C). Moreover, 
following Impella treatment, LVEF improved significantly 
from baseline to discharge (figure 1D).
Feasibility and safety
Both devices were successfully implanted in all patients. 
The balloon size of the IABP was 40 cm3. An Impella 2.5 
was implanted in 19 (31%) and an Impella CP in 43 (69%) 
patients. The complications occurring from the time of 
device implantation until discharge are summarised in 
table 5. Rates of stroke, MI and TVR were similar in both 
groups (Impella vs IABP: 1.6% vs 1.8, p=1.00; 1.6% vs 
5.5%, p=0.48% and 3.2% vs 0%, p=0.43). No significant 
differences in the rate of pericardial effusion (1.6% vs 
5.5%, p=0.33) or cardiac tamponade requiring interven-
tion (3.2% vs 3.7%, p=1.00) were observed. Furthermore, 
rates of bleeding BARC 2 and 3, (14.5% vs 7.4%, p=0.25) 
and limb ischaemia (8% vs 0%, p=0.06) were similar 
among the device groups but showed a strong trend of 
higher frequency in Impella-treated patients. Moreover, 
the number of transfused erythrocytes concentrates 
due to bleeding complications was significantly higher 
following the Impella placement (4 vs 3 units, p=0.03).
Outcomes at 30 days
Mortality at 30 days and detailed causes of death are 
depicted in the online supplementary file 1. Overall, 
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Table 5 Complications
IABP
(N=54)
Impella
(N=62) P value
Stroke 1 (1.8) 1 (1.6) 1.00
MI 3 (5.5) 1 (1.6) 0.48
TVR 0 (0) 2 (3.2) 0.43
Pericardial effusion 3 (5.5) 1 (1.6) 0.33
Pericardial tamponade 2 (3.7) 2 (3.2) 1.00
Limb ischaemia 0 (0) 5 (8.0) 0.06
Bleeding BARC 2 and 3 4 (7.4) 9 (14.5) 0.25
Number of RBCs 3(2-4) 4(4-7) 0.03
Number of FFPs 4(2-6) 2(2-7) 0.60
Data depicted as median (IQR) or counts (%). P-values are from 
Wilcoxon rank sum or Fischer test.
BARC 2, Bleeding Academic Research Consortium type 2; 
BARC 3, Bleeding Academic Research Consortium type 3; FFP, 
fresh frozen plasma; MI, myocardial infarction; RBC, red blood 
concentrate; TVR, target vessel revascularisation.
all-cause mortality was 59%, with no significant differ-
ences between the Impella and IABP group (52% and 
67%, p=0.13). The most frequent cause of death in both 
groups was heart failure from AMICS (43%). Notably, 
numerically fewer patients died of heart failure from 
AMICS in the Impella-treated group (36% and 52%, 
p=0.09; online supplementary file 1). Other causes of 
death were multiorgan failure due to systemic inflamma-
tory response syndrome (SIRS, Impella 11% and IABP 
5.5%-; p=0.33), and palliation from irreversible postan-
oxic brain damage (4.8% and 9.3%, p=0.47). Overall, 
6.9% of patients underwent palliation for irreversible 
postanoxic brain damage with no significant differences 
among the treatment groups (4.8% and 9.3%, p=0.47). 
In a subgroup analysis, after excluding deaths from palli-
ation due to postanoxic brain damage, 30-day mortality 
due to heart failure from AMICS, did not reach statistical 
significance in Impella-treated patients (37% and 57%, 
p=0.05, online supplementary file 1. In Kaplan-Meier 
analysis, all-cause mortality did not differ between the two 
treatment groups, regardless of whether patients under-
going palliation were (p=0.13, figure 2A) or were not 
(p=0.23, figure 2B) included in the analysis. After stratifi-
cation according to the baseline estimated IABP-SHOCK 
II risk score, no survival benefit of Impella was observed 
in either subgroup (figure 2C, D).
Independent predictors of 30-day mortality
In multivariate analysis, treatment with Impella showed 
no significant effect on mortality (HR 0.82, 95% CI 0.50 
to 1.36; p=0.45). Previous CPR (HR 3.22, 95% CI 1.76 
to 5.89; p<0.01) and estimated, intermediate (HR 2.77, 
95% CI 1.42 to 5.40; p<0.01) and high (HR 4.32 95% CI 
2.03 to 9.24; p=0.01) IABP-SHOCK II risk score, consid-
erably increased the risk of mortality (figure 3A). In the 
subgroup of patients with estimated low-intermediate 
risk, no significant effect on mortality after treatment 
with Impella was observed (HR 0.59, 95% CI 0.34 to 1.04; 
p=0.07; figure 3B).
dIsCussIOn
To our knowledge, this is one of the largest historical 
cohorts investigating the benefit of haemodynamic 
support with Impella versus IABP in patients with severe 
AMICS.
The following findings emerged from our study. First, 
compared with IABP, treatment with Impella significantly 
improves parameters of shock severity and LVEF. Second, 
at 30 days, there is no significant benefit in all-cause 
mortality compared with IABP. Third, there is no signifi-
cant increase in rates of stroke, reinfarction and TVR but 
treatment with Impella was associated with a significantly 
higher number of transfused erythrocytes concentrates 
due to bleeding complications.
AMICS is a complex disease, still associated with a 
mortality of 40%–75% despite early revascularisation.20 
Impella has been frequently used in this clinical setting 
due to its feasibility and safety in emergency conditions 
and the benefits of ventricular unloading, supported 
from preclinical and clinical data.7 9 21 Superior haemo-
dynamic support provided by Impella explains the signif-
icant reduction of lactate levels and SAPS II and the lower 
inotropic scores observed in our study. However, the CPI, 
length of ICU stay, the rate of mechanical ventilation and 
that of RRT were not different from patients treated with 
IABP. The onset of multiorgan failure due to SIRS, occur-
ring in 11% of patients receiving Impella versus 5.5% of 
those receiving IABP, might have obscured the beneficial 
effects provided by the latter. The results of our study 
are in line with those of the Impella versus Intra-Aortic 
Balloon Pump in Cardiogenic Shock trial, a metanalysis 
of existing RCTs, and a recent multicentre retrospective 
registry, all demonstrating the lack of benefit of Impella 
in reducing 30 day mortality.11 22 23 These studies included 
patients presenting in different stages of shock severity, 
while to date, the profile of patients with AMICS who may 
profit from pMCS remains still unclear. In fact, a benefit 
in terms of reduction in 30-day mortality with Impella, 
as compared with standard medical therapy or IABP, 
has not been shown in any clinical setting and for any 
pMCS for that matter. AMICS is indeed a condition with 
broad severity of presentation. Approximately 50% of 
patients survive AMICS without pMCS,4 on the contrary, 
pMCS might be futile in others because of the advanced 
state of disease. Therefore, an accurate risk stratification 
early in this emergency setting can help guide further 
clinical decision and refine patient selection towards 
achieving a real benefit from pMCS devices. Previous 
studies suggested a protective effect exerted by Impella 
in ‘lower risk’ patients.24 According to the results of the 
recently published ‘Detroit Cardiogenic Shock Initiative’, 
the rapid delivery of Impella was beneficial in patients 
presenting in a still responsive shock stage. The authors 
implemented a regional protocol based on rapid early 
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Figure 2 Kaplan-Meier estimates of all-cause mortality at 30 days. Depicted are the Kaplan-Meier estimates of all-cause 
mortality at 30 days. P-values from the log-rank test. events were analysed (A) in the whole study population, (B) after excluding 
deaths due to palliation by irreversible postanoxic brain damage, (C) in the low-intermediate and (D) high IABP-SHOCK II risk 
score subgroup. IABP-SHOCK II, Intra-aortic Balloon Pump in Cardiogenic Shock II.
delivery of pMCS within 90 min of shock onset and early 
discontinuation of inotropic and vasopressors, being able 
to show an improvement of mortality compared with 
institutional historical cohorts.24 In our study, we did not 
find a significant difference in 30-day mortality after strat-
ifying the patients according to the IABP-SHOCK II risk 
score. In fact, the estimated mortality rate in the low-in-
termediate risk group was approximately 60%–70%, 
reflecting the bailout character of Impella use in these 
patients with poor a haemodynamic profile. Although in 
the Detroit study the cohort was highly preselected, the 
results of the study indicate that in ‘lower-risk‘ patients, 
the benefits of early pMCS implantation merit further 
investigation in appropriately powered trials.
In patients with high IABP-SHOCK II risk score, support 
with Impella is clearly futile. In this clinical setting, it 
was recently shown that the combination of Impella and 
venoarterial extracorporeal membrane oxygenation 
(VA-ECMO) provides a more robust haemodynamic 
support and is superior to VA-ECMO alone.18
The present study has several limitations. First, due to 
the nature of the retrospective design, comprehending 
patients from a historical cohort, residual confounding 
cannot be excluded even after multivariable adjustments. 
Second, despite being considerable compared with 
other studies, the size of our cohort was insufficient to 
detect significant differences in mortality. Finally, despite 
applying strict criteria for patient selection, there was 
some degree of heterogeneity, probably due to the lack 
of evidence in the use of pMCS devices.
In conclusion, the debate on Impella is still ongoing, 
in a scenario where, the mortality benefit of any available 
percutaneous device has still to be proven in an RCT. Due 
to the difficulty of conducting trials in this emergency 
setting, data from observational studies are important 
and should serve at least as hypothesis generating. In 
Open Heart
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Figure 3 Independent predictors of all-cause mortality at 30 days. (HRs are from COX regressions with 95% CIs). Events were 
analysed (A) in the whole study population and (B) in the subgroup of patientswith low-intermediate IABP-SHOCK II score. 
adjustment covariates including IABP-SHOCK II risk score and CPR. CPR, cardiopulmonary resuscitation; IABP-SHOCK II, 
Intra-aortic Balloon Pump in Cardiogenic Shock II.
this large retrospective study, we observed that haemody-
namic support with Impella is feasible and improves the 
parameters of shock severity compared with former stan-
dard IABP. Impella does not improve 30-day mortality, 
however, a possible benefit in selected patients with 
lower estimated mortality risk should be investigated in 
adequately powered RCTs.
Data depicted as median (IQR) or counts (%). P values 
are from Wilcoxon rank sum or Fischer’s test. AMI-acute 
myocardial infarction, BMI-Body Mass Index, CABG-cor-
onary artery bypass graft, CAD-coronary artery disease, 
CKD-chronic kidney disease, CPR-cardiopulmonary resus-
citation, CRP-C-reactive Protein, CRT-cardiac resynchro-
nization therapy, IABP-SHOCK II- short-term mortality 
risk score, LDH-Lactate Dehydrogenase, MI-myocar-
dial infarction NIDDM-non-insulin dependent diabetes 
mellitus, PCI-percutaneous coronary angioplasty, Pre-PCI 
time-time from symptom onset to the first PCI balloon 
inflation, Pre-device time-time from symptom onset to 
device implantation.
Data depicted as counts (%). P values are from Fisch-
er’s test. IABP-SHOCK II-Intra-aortic Balloon Pump in 
Cardiogenic Shock II. Data on the IABP Shock II risk 
score was not retrievable for five patients.
Data depicted as median (IQR) or counts (%). P 
values are from Wilcoxon rank sum or Fischer’s test. 
CK-max.-maximal Creatine-Kinase, CK-MB-Creatine-Ki-
nase Isoform MB, CPR-cardiopulmonary resuscitation, 
LVEF-left ventricular ejection fraction (%), TIMI-Throm-
bolysis in Myocardial Infarction. SAPS II-Simplified Acute 
Physiology Score II. * Data on TIMI III flow after PCI 
was not retrievable for two patients in the IABP and one 
patient in the Impella group.
Data depicted as median (IQR) or counts (%). P values 
are from Wilcoxon rank sum or Fischer’s test. ICU- Inten-
sive care unit.
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Data depicted as median (IQR) or counts (%). P values 
are from Wilcoxon rank sum or Fischer’s test. BARC 2 
and 3-Bleeding Academic Research Consortium type 2 
and 3, FFP-Fresh Frozen Plasma, MI-myocardial infarc-
tion, RBC-Red Blood Concentrate, TVR-target vessel 
revascularisation.
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